SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
jgh12283-sup-0001-si.zip432K

Figure S1 The impact of baseline serum HBsAg levels on HBV DNA virological breakthrough among patients with HBeAg-negative chronic hepatitis B who received lamivudine therapy. (a) The cumulative virological breakthrough rates were similar between patients with baseline HBsAg levels ≥ 2000 IU/mL and those with < 2000 IU/mL (P = 0.905). (b) Among patients with serum HBV DNA < 2000 IU/mL at 6 months post-therapy, the cumulative virological breakthrough was comparable between patients with baseline HBsAg levels ≥ 2000 IU/mL and those with < 2000 IU/mL in HBeAg-negative patients (P = 0.761).

Table S1 Comparison of demographic data between patients infected with genotype B and C HBV.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.